Hao Yin Ph.D.

Dr. Hao Yin received his B.S. degree in Biotechnology from Nanjing University in Nanjing, China and completed his PhD training at the University of Colorado Anschutz Medical Campus. In December 2010, He joined the research group of Professor Robert Langer and Professor Daniel Anderson at Massachusetts Institute of Technology. At Langer/Anderson lab, he harnessed novel viral and non-viral delivery vectors, in vivo siRNA and genome engineering technologies for generating cancer models, and developing cancer therapeutics and gene-based therapy. He spearheaded the first demonstration that CRISPR can reverse disease symptoms in living animals, extending its application from in vitro to in vivo. His work, published in 2014 in Nature Biotechnology, has been highlighted in front-page headlines and as cover stories by numerous influential public media and scientific journals worldwide. For example, this paper was selected as 100 top stories of 2014 as A Giant Step for Gene Surgery by Discover Magazine. In collaborations with the laboratories of Professor Phillip Sharp and Professor Tyler Jacks, he is the leading author in another landmark study published in 2014 in Nature, demonstrating that CRISPR can directly mutate tumor suppressor genes and oncogenes in vivo, creating a new avenue for the rapid development of cancer models and functional genomics. With expertise in non-viral vectors, he generated clinical suitable delivery methods for CRISPR mediated in vivo gene repair. Published in 2016 in Nature Biotechnology, he developed a lipid-based nanoformulation of Cas9 mRNA for in vivo delivery (named as Nano.Cas9). When Nano.Cas9 was combined with an adenovirus-associated virus vector carrying a guide RNA and a repair template, this treatment induced gene repair with high efficiency and minimal off-target genomic effects in the liver.